The effect of ascorbic acid in reducing nephrotoxicity caused by vancomycin

Investigating the effect of ascorbic acid in reducing vancomycin-induced nephrotoxicity: a double-blind randomized clinical trial study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241109063646N1

Enrollment

Registered

2024-12-01

Start date

2024-12-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Investigating the effect of injectable ascorbic acid in reducing vancomycin nephrotoxicity.

Interventions

Intervention 1: Intervention group: Patients receiving ascorbic acid and vancomycin from the first day to a minimum of 4 days and a maximum of 28 days from the start of treatment with vancomycin, vanc

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ?Age above 18 years Receiving vancomycin for at least 4 days as empiric or culture-based treatment for vancomycin susceptible MRSA

Exclusion criteria

Exclusion criteria: History of sensitivity to vancomycin or ascorbic acid Pregnant and lactating women GFR below 30 Receiving other antioxidants (vitamin E, N-acetylcysteine, melatonin) while receiving vancomycin Receiving other antioxidants (vitamin E, N-acetylcysteine, melatonin) while receiving vancomycin

Design outcomes

Primary

Measure	Time frame
Decreased serum creatinine. Timepoint: Daily up to a maximum of 10 days. Method of measurement: It is checked daily through blood tests and registration of questionnaires.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Rahmanian

Yazd University of Medical Sciences

rah_marjan@yahoo.com+98 35 3823 9094

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026